Teva Pharmaceutical Industries (NYSE:TEVA) Cut to “Hold” at StockNews.com

StockNews.com lowered shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a buy rating to a hold rating in a research report released on Monday morning.

TEVA has been the topic of several other research reports. Barclays reduced their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. UBS Group reduced their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Piper Sandler increased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Finally, Bank of America decreased their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, March 6th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and a consensus target price of $23.43.

Teva Pharmaceutical Industries Stock Down 1.3 %

Shares of TEVA stock opened at $13.42 on Monday. The company’s fifty day simple moving average is $15.57 and its two-hundred day simple moving average is $17.73. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $22.80. The stock has a market cap of $15.22 billion, a P/E ratio of -9.26, a PEG ratio of 1.44 and a beta of 0.72. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Analysts predict that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several hedge funds have recently bought and sold shares of TEVA. Diversify Advisory Services LLC boosted its stake in shares of Teva Pharmaceutical Industries by 2.5% during the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company’s stock valued at $426,000 after purchasing an additional 496 shares during the period. Sanctuary Advisors LLC grew its stake in Teva Pharmaceutical Industries by 1.9% in the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock worth $601,000 after acquiring an additional 664 shares in the last quarter. Thrivent Financial for Lutherans increased its position in shares of Teva Pharmaceutical Industries by 0.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company’s stock worth $4,964,000 after acquiring an additional 699 shares during the period. Townsquare Capital LLC raised its stake in shares of Teva Pharmaceutical Industries by 2.1% during the fourth quarter. Townsquare Capital LLC now owns 40,162 shares of the company’s stock valued at $885,000 after acquiring an additional 812 shares in the last quarter. Finally, Metis Global Partners LLC raised its position in Teva Pharmaceutical Industries by 6.7% during the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company’s stock valued at $302,000 after purchasing an additional 860 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.